Iovance Biotherapeutics, Inc.
IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candiā¦ read more
Healthcare
Biotechnology
15 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.29
Price-7.79%
-$0.70
1Y
Price
Market Cap
$3.702b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-99.6%
EBITDA Margin-110.7%
Net Profit Margin-110.2%
Free Cash Flow Margin-99.6%
EBITDA Margin-110.7%
Net Profit Margin-110.2%
Free Cash Flow MarginRevenue
$285.608m
+8.4%
1y CAGR+4589.3%
3y CAGR+3442.0%
5y CAGREarnings
-$353.860m
+9.5%
1y CAGR+6.9%
3y CAGR+2.1%
5y CAGREPS
-$0.92
+15.6%
1y CAGR+20.9%
3y CAGR+21.7%
5y CAGRBook Value
$721.754m
$925.665m
Assets$203.911m
Liabilities$47.776m
DebtDebt to Assets
5.2%
-0.1x
Debt to EBITDAFree Cash Flow
-$305.021m
+9.3%
1y CAGR+7.4%
3y CAGR-0.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company